AP NEWS

Lung Transplant Rejection Pipeline Review H1 2018 - Reviews Key Companies Involved in Therapeutics and Enlists All Their Major & Minor Projects - ResearchAndMarkets.com

June 5, 2018

DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Lung Transplant Rejection - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

The pipeline guide provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection (Immunology).

The pipeline guide reviews pipeline therapeutics for Lung Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Lung Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Lung Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Lung Transplant Rejection (Immunology).

Companies Mentioned

Astellas Pharma Inc Kamada Ltd MimeTech Srl Novartis AG Quark Pharmaceuticals Inc TxCell SA

Key Topics Covered

Introduction Report Coverage Lung Transplant Rejection - Overview Lung Transplant Rejection - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Lung Transplant Rejection - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Lung Transplant Rejection - Companies Involved in Therapeutics Development Astellas Pharma Inc Kamada Ltd MimeTech Srl Novartis AG Quark Pharmaceuticals Inc TxCell SA Lung Transplant Rejection - Drug Profiles alpha-1 proteinase inhibitor (human) - Drug Profile Product Description Mechanism Of Action R&D Progress BC-1261 - Drug Profile Product Description Mechanism Of Action R&D Progress FX-06 - Drug Profile Product Description Mechanism Of Action R&D Progress MT-8 - Drug Profile Product Description Mechanism Of Action R&D Progress QPI-1024 - Drug Profile Product Description Mechanism Of Action R&D Progress QPLI-1 - Drug Profile Product Description Mechanism Of Action R&D Progress R-554 - Drug Profile Product Description Mechanism Of Action R&D Progress R-801 - Drug Profile Product Description Mechanism Of Action R&D Progress tacrolimus - Drug Profile Product Description Mechanism Of Action R&D Progress tiprelestat - Drug Profile Product Description Mechanism Of Action R&D Progress TX-200 - Drug Profile Product Description Mechanism Of Action R&D Progress Zortress - Drug Profile Product Description Mechanism Of Action R&D Progress Lung Transplant Rejection - Dormant Projects Lung Transplant Rejection - Product Development Milestones Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/65cx2m/lung_transplant?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006655/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immunosuppressive Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 03:50 PM/DISC: 06/05/2018 03:50 PM

http://www.businesswire.com/news/home/20180605006655/en

AP RADIO
Update hourly